Although it sounds like an oxymoron, high-growth prospect dividend aristocrat stocks exist, although their industries may ...

Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales ...

Abbvie's stock rises 4.51% despite looming trade tensions and competitive pressures. Analysts from Morgan Stanley, Raymond ...

North Chicago, Illinois-based AbbVie Inc. has shown a robust performance despite market fluctuations. While the broader ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

This was the stock's second consecutive day of gains.

Allergan Aesthetics scored a big legal patent infringement win tied to its blockbuster wrinkle-treatment Botox. A federal ...

Please provide your email address to receive an email when new articles are posted on . This activity is supported by independent medical education grants from 4D Molecular Therapeutics; AbbVie ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 ...